Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 12917691)

  • 1. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
    Kovalenko A; Chable-Bessia C; Cantarella G; Israël A; Wallach D; Courtois G
    Nature; 2003 Aug; 424(6950):801-5. PubMed ID: 12917691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
    Trompouki E; Hatzivassiliou E; Tsichritzis T; Farmer H; Ashworth A; Mosialos G
    Nature; 2003 Aug; 424(6950):793-6. PubMed ID: 12917689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.
    Brummelkamp TR; Nijman SM; Dirac AM; Bernards R
    Nature; 2003 Aug; 424(6950):797-801. PubMed ID: 12917690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation.
    Reiley W; Zhang M; Wu X; Granger E; Sun SC
    Mol Cell Biol; 2005 May; 25(10):3886-95. PubMed ID: 15870263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation [corrected].
    Wu CJ; Conze DB; Li T; Srinivasula SM; Ashwell JD
    Nat Cell Biol; 2006 Apr; 8(4):398-406. PubMed ID: 16547522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway.
    Jono H; Lim JH; Chen LF; Xu H; Trompouki E; Pan ZK; Mosialos G; Li JD
    J Biol Chem; 2004 Aug; 279(35):36171-4. PubMed ID: 15226292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The K48-K63 Branched Ubiquitin Chain Regulates NF-κB Signaling.
    Ohtake F; Saeki Y; Ishido S; Kanno J; Tanaka K
    Mol Cell; 2016 Oct; 64(2):251-266. PubMed ID: 27746020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase.
    Pomerantz JL; Baltimore D
    EMBO J; 1999 Dec; 18(23):6694-704. PubMed ID: 10581243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative regulation of JNK signaling by the tumor suppressor CYLD.
    Reiley W; Zhang M; Sun SC
    J Biol Chem; 2004 Dec; 279(53):55161-7. PubMed ID: 15496400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation and function of IKK and IKK-related kinases.
    Häcker H; Karin M
    Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.
    Almeida S; Maillard C; Itin P; Hohl D; Huber M
    J Invest Dermatol; 2008 Mar; 128(3):587-93. PubMed ID: 17851586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
    Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
    Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.
    Karin M; Ben-Neriah Y
    Annu Rev Immunol; 2000; 18():621-63. PubMed ID: 10837071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-kappaB activation through IKK-i-dependent I-TRAF/TANK phosphorylation.
    Nomura F; Kawai T; Nakanishi K; Akira S
    Genes Cells; 2000 Mar; 5(3):191-202. PubMed ID: 10759890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.
    Yoshida H; Jono H; Kai H; Li JD
    J Biol Chem; 2005 Dec; 280(49):41111-21. PubMed ID: 16230348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
    Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
    Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin signalling in the NF-kappaB pathway.
    Chen ZJ
    Nat Cell Biol; 2005 Aug; 7(8):758-65. PubMed ID: 16056267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of CYLD might be associated with development of salivary gland tumors.
    Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
    Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
    Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
    In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
    Massoumi R; Chmielarska K; Hennecke K; Pfeifer A; Fässler R
    Cell; 2006 May; 125(4):665-77. PubMed ID: 16713561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.